The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Intracellular Regulation of TRAIL-Induced Apoptosis in Human Melanoma Cells
Open accessAbstract
The observation that TNF-related apoptosis-inducing ligand (TRAIL), a member of the TNF cytokine family, induces apoptosis in a number of different tumor cell types led us to compare the tumoricidal effects of TRAIL to those of other TNF family molecules on human melanoma cells. We found that a high proportion of the melanoma cell lines tested were killed by TRAIL, whereas all the melanoma lines were resistant to the other TNF family cytokines tested. TRAIL-induced death was characterized by caspase activation and cellular protein cleavage within minutes of TRAIL addition, and death could be completely inhibited by the caspase inhibitors Ile-Glu-Thr-Asp (IETD) and Val-Ala-Asp (VAD), indicating the presence of a TRAIL receptor signaling pathway similar to that identified for Fas and TNF receptors. Specific TRAIL receptor expression was determined by RT-PCR, and the presence of mRNA encoding the “protective” TRAIL receptors did not correspond to resistance or sensitivity to TRAIL-induced apoptosis. Addition of protein synthesis inhibitors to TRAIL-resistant melanomas rendered them sensitive to TRAIL, indicating that the presence or the absence of intracellular apoptosis inhibitors may mediate resistance or sensitivity to TRAIL-mediated apoptosis. Expression of one such inhibitor, FLICE-inhibitory protein (FLIP), was highest in the TRAIL-resistant melanomas, while being low or undetectable in the TRAIL-sensitive melanomas. Furthermore, addition of actinomycin D to TRAIL-resistant melanomas resulted in decreased intracellular concentrations of FLIP, which correlated with their acquisition of TRAIL sensitivity. Collectively, our results indicate that TRAIL-induced apoptosis occurs through a caspase signaling cascade and that resistance is controlled by intracellular regulators of apoptosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apoptosis in the Pathogenesis and Treatment of Disease
Thompson, C. B. (1995) · Science · doi:10.1126/science.7878464 · Cited by 6,524
Nagata, S., & Golstein, P. (1995) · Science · doi:10.1126/science.7533326 · Cited by 3,979
Identification and characterization of a new member of the TNF family that induces apoptosis
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900
Inhibition of death receptor signals by cellular FLIP
Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Steiner, V., Bodmer, J.-L., Schröter, M., Burns, K., Mattmann, C., et al. (1997) · Nature · doi:10.1038/40657 · Cited by 2,563
Nicholson, D. W., & Thornberry, N. A. (1997) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(97)01085-2 · Cited by 2,409
Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege
Griffith, T. S., Brunner, T., Fletcher, S. M., Green, D. R., & Ferguson, T. A. (1995) · Science · doi:10.1126/science.270.5239.1189 · Cited by 2,005
Self-citationKaufmann, S. H., Desnoyers, S., Ottaviano, Y. L., Davidson, N. E., & Poirier, G. G. (1993) · PubMed · Cited by 1,889
The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death
Smith, C. A., Farrah, T., & Goodwin, R. G. (1994) · Cell · doi:10.1016/0092-8674(94)90372-7 · Cited by 1,887
Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family
Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., & Ashkenazi, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.12687 · Cited by 1,793
The Receptor for the Cytotoxic Ligand TRAIL
Pan, G., O'Rourke, K., Chinnaiyan, A. M., Gentz, R., Ebner, R., Ni, J., & Dixit, V. M. (1997) · Science · doi:10.1126/science.276.5309.111 · Cited by 1,767
Cited by
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497
Self-citationOverview of cell death signaling pathways
Jin, Z., & El-Deiry, W. S. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.2.1508 · Cited by 1,326
NF-kB in development and progression of human cancer
Dolcet, X., Llobet, D., Pallares, J., & Matias-Guiu, X. (2005) · Virchows Archiv · doi:10.1007/s00428-005-1264-9 · Cited by 1,169
Apo2L/TRAIL-Dependent Recruitment of Endogenous FADD and Caspase-8 to Death Receptors 4 and 5
Kischkel, F. C., Lawrence, D. A., Chuntharapai, A., Schow, P., Kim, K. J., & Ashkenazi, A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80212-5 · Cited by 975
TRAIL and apoptosis induction by TNF-family death receptors
Wang, S., & El-Deiry, W. S. (2003) · Oncogene · doi:10.1038/sj.onc.1207232 · Cited by 871
Apo2L/TRAIL and its death and decoy receptors
LeBlanc, H. N., & Ashkenazi, A. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401187 · Cited by 854
Sprick, M. R., Weigand, M. A., Rieser, E., Rauch, C. T., Juo, P., Blenis, J., Krammer, P. H., & Walczak, H. (2000) · Immunity · doi:10.1016/s1074-7613(00)80211-3 · Cited by 794
An immune-active tumor microenvironment favors clinical response to ipilimumab
Ji, R.-R., Chasalow, S. D., Wang, L., Hamid, O., Schmidt, H., Cogswell, J., Alaparthy, S., Berman, D., Jure-Kunkel, M., Siemers, N. O., et al. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1172-6 · Cited by 775
Mechanisms of resistance to TRAIL-induced apoptosis in cancer
Zhang, L., & Fang, B. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700792 · Cited by 702
The CD95 (APO-1/Fas) and the TRAIL (APO-2L) Apoptosis Systems
Walczak, H., & Krammer, P. H. (2000) · Experimental Cell Research · doi:10.1006/excr.2000.4840 · Cited by 628
c-FLIPL is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis
Chang, D. W. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf356 · Cited by 563
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy
Almasan, A., & Ashkenazi, A. (2003) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(03)00029-7 · Cited by 553
Chinnaiyan, A. M., Prasad, U., Shankar, S., Hamstra, D. A., Shanaiah, M., Chenevert, T. L., Ross, B. D., & Rehemtulla, A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.030545097 · Cited by 530
Monocyte-mediated Tumoricidal Activity via the Tumor Necrosis Factor–related Cytokine, TRAIL
Griffith, T. S., Wiley, S. R., Kubin, M. Z., Sedger, L. M., Maliszewski, C. R., & Fanger, N. A. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.8.1343 · Cited by 476
Self-citationImmune escape of tumors: apoptosis resistance and tumor counterattack
Igney, F. H., & Krammer, P. H. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.6.907 · Cited by 468
Takeda, K., Smyth, M. J., Cretney, E., Hayakawa, Y., Kayagaki, N., Yagita, H., & Okumura, K. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011171 · Cited by 465
TRAIL: a molecule with multiple receptors and control mechanisms
Griffith, T. S., & Lynch, D. H. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80224-0 · Cited by 453
Self-citationDjerbi, M., Screpanti, V., Catrina, A. I., Bogen, B., Biberfeld, P., & Grandien, A. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.7.1025 · Cited by 421
Suliman, A., Lam, A., Datta, R., & Srivastava, R. K. (2001) · Oncogene · doi:10.1038/sj.onc.1204282 · Cited by 419
Fanger, N. A., Maliszewski, C. R., Schooley, K., & Griffith, T. S. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.8.1155 · Cited by 413
Self-citationMitsiades, C. S., Treon, S. P., Mitsiades, N., Shima, Y., Richardson, P., Schlossman, R., Hideshima, T., & Anderson, K. C. (2001) · Blood · doi:10.1182/blood.v98.3.795 · Cited by 392
Regulation of lymphocyte proliferation and death by flip
Thome, M., & Tschopp, J. (2001) · Nature Reviews Immunology · doi:10.1038/35095508 · Cited by 378
Expression and Targeting of the Apoptosis Inhibitor, Survivin, in Human Melanoma
Grossman, D., McNiff, J. M., Li, F., & Altieri, D. C. (1999) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1999.00776.x · Cited by 365
Chawla-Sarkar, M., Bae, S. I., Reu, F. J., Jacobs, B. S., Lindner, D. J., & Borden, E. C. (2004) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401416 · Cited by 359
Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential
Shankar, S. (2007) · Frontiers in Bioscience · doi:10.2741/2432 · Cited by 342
Immune Escape of Tumors in Vivo by Expression of Cellular Flice-Inhibitory Protein
Medema, J. P., de Jong, J., van Hall, T., Melief, C. J. M., & Offringa, R. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.7.1033 · Cited by 330
Kim, Y., Suh, N., Sporn, M., & Reed, J. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202458200 · Cited by 309
Mechanisms of HIV-associated lymphocyte apoptosis
Badley, A. D., Pilon, A. A., Landay, A., & Lynch, D. H. (2000) · Blood · doi:10.1182/blood.v96.9.2951 · Cited by 308
Self-citationDifferential Inhibition of TRAIL-Mediated DR5-DISC Formation by Decoy Receptors 1 and 2
Mérino, D., Lalaoui, N., Morizot, A., Schneider, P., Solary, E., & Micheau, O. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00520-06 · Cited by 305
Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer
Chen, X., Thakkar, H., Tyan, F., Gim, S., Robinson, H., Lee, C., Pandey, S. K., Nwokorie, C., Onwudiwe, N., & Srivastava, R. K. (2001) · Oncogene · doi:10.1038/sj.onc.1204736 · Cited by 298
Zamai, L., Ponti, C., Mirandola, P., Gobbi, G., Papa, S., Galeotti, L., Cocco, L., & Vitale, M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.7.4011 · Cited by 292
Immunity to cancer: attack and escape in T lymphocyte–tumor cell interaction
Rivoltini, L., Carrabba, M., Huber, V., Castelli, C., Novellino, L., Dalerba, P., Mortarini, R., Arancia, G., Anichini, A., Fais, S., et al. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18809.x · Cited by 289
Cell surface Death Receptor signaling in normal and cancer cells
Özören, N., & El-Deiry, W. S. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00131-1 · Cited by 289
Regulation of death receptor-mediated apoptosis pathways
Schmitz, I., Kirchhoff, S., & Krammer, P. H. (2000) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(00)00048-0 · Cited by 288
Fotin-Mleczek, M., Henkler, F., Samel, D., Reichwein, M., Hausser, A., Parmryd, I., Scheurich, P., Schmid, J. A., & Wajant, H. (2002) · Journal of Cell Science · doi:10.1242/jcs.115.13.2757 · Cited by 284
TRAIL/Apo-2L: Mechanisms and Clinical Applications in Cancer
Srivastava, R. K. (2001) · Neoplasia · doi:10.1038/sj.neo.7900203 · Cited by 280
Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis
Hinz, S., Trauzold, A., Boenicke, L., Sandberg, C., Beckmann, S., Bayer, E., Walczak, H., Kalthoff, H., & Ungefroren, H. (2000) · Oncogene · doi:10.1038/sj.onc.1203936 · Cited by 275
Apoptosis and melanoma: molecular mechanisms
Hussein, M. R., Haemel, A. K., & Wood, G. S. (2003) · The Journal of Pathology · doi:10.1002/path.1300 · Cited by 272
TRAIL receptor signalling and modulation: Are we on the right TRAIL?
Mahalingam, D., Szegezdi, E., Keane, M., Jong, S. D., & Samali, A. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.11.006 · Cited by 272
Phosphatidylinositol 3-Kinase/Akt Activity Regulates c-FLIP Expression in Tumor Cells
Panka, D. J., Mano, T., Suhara, T., Walsh, K., & Mier, J. W. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c000569200 · Cited by 269
Elevated Akt Activity Protects the Prostate Cancer Cell Line LNCaP from TRAIL-induced Apoptosis
Nesterov, A., Lu, X., Johnson, M., Miller, G. J., Ivashchenko, Y., & Kraft, A. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m005196200 · Cited by 269
Alterations in the apoptotic machinery and their potential role in anticancer drug resistance
Kaufmann, S. H., & Vaux, D. L. (2003) · Oncogene · doi:10.1038/sj.onc.1206945 · Cited by 265
Apoptosis regulators and responses in human melanocytic and keratinocytic cells
Bowen, A. R., Hanks, A. N., Allen, S. M., Alexander, A., Diedrich, M. J., & Grossman, D. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12010.x · Cited by 149
(2001) · PubMed · Cited by 130
Evdokiou, A., Bouralexis, S., Atkins, G. J., Chai, F., Hay, S., Clayer, M., & Findlay, D. M. (2002) · International Journal of Cancer · doi:10.1002/ijc.10376 · Cited by 129
Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis
Kontny, H. U., Hämmerle, K., Klein, R., Shayan, P., Mackall, C. L., & Niemeyer, C. M. (2001) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400836 · Cited by 90
Metadata
- Authors
- Griffith, T. S., Chin, W. A., Jackson, G. C., Lynch, D. H., & Kubin, M. Z.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-09
- Volume
- 161
- Issue
- 6
- Pages
- 2833-2840
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2098439946
- Cited by
- 664
- References
- 46
- FWCI
- 18.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.